CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other Events

Item8.01.

On June19, 2017, CRISPR Therapeutics AG (the Company) announced
that Chinas State Intellectual Property Office has granted a
patent broadly covering the Companys in-licensed gene editing
technology. A copy of the press release announcing the grant of
the patent is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not
filed:

CRISPR Therapeutics AG Exhibit
EX-99.1 2 d417591dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China     •   Patent includes CRISPR/Cas9 gene editing methods and compositions for use in any non-cellular and cellular setting,…
To view the full exhibit click here
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.